Physician and stakeholder perceptions of conflict of interest policies in oncology.

A. Craig Lockhart, Marcia S. Brose, Edward S. Kim, David H. Johnson, Jeffrey M. Peppercorn, Dina L. Michels, Courtney D. Storm, Lynn M. Schuchter, W. Kimryn Rathmell

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The landscape of managing potential conflicts of interest (COIs) has evolved substantially across many disciplines in recent years, but rarely are the issues more intertwined with financial and ethical implications than in the health care setting. Cancer care is a highly technologic arena, with numerous physician-industry interactions. The American Society of Clinical Oncology (ASCO) recognizes the role of a professional organization to facilitate management of these interactions and the need for periodic review of its COI policy (Policy). To gauge the sentiments of ASCO members and nonphysician stakeholders, two surveys were performed. The first asked ASCO members to estimate opinions of the Policy as it relates to presentation of industry-sponsored research. Respondents were classified as consumers or producers of research material based on demographic responses. A similar survey solicited opinions of nonphysician stakeholders, including patients with cancer, survivors, family members, and advocates. The ASCO survey was responded to by 1,967 members (1% of those solicited); 80% were producers, and 20% were consumers. Most respondents (93% of producers; 66% of consumers) reported familiarity with the Policy. Only a small proportion regularly evaluated COIs for presented research. Members favored increased transparency about relationships over restrictions on presentations of research. Stakeholders (n = 264) indicated that disclosure was "very important" to "extremely important" and preferred written disclosure (77%) over other methods. COI policies are an important and relevant topic among physicians and patient advocates. Methods to simplify the disclosure process, improve transparency, and facilitate responsiveness are critical for COI management.

Original languageEnglish (US)
Pages (from-to)1677-1682
Number of pages6
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume31
Issue number13
DOIs
StatePublished - May 1 2013

Fingerprint

Conflict of Interest
Medical Oncology
Physicians
Disclosure
Research
Industry
Survivors
Neoplasms
Demography
Surveys and Questionnaires
Delivery of Health Care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Physician and stakeholder perceptions of conflict of interest policies in oncology. / Lockhart, A. Craig; Brose, Marcia S.; Kim, Edward S.; Johnson, David H.; Peppercorn, Jeffrey M.; Michels, Dina L.; Storm, Courtney D.; Schuchter, Lynn M.; Rathmell, W. Kimryn.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 31, No. 13, 01.05.2013, p. 1677-1682.

Research output: Contribution to journalArticle

Lockhart, A. Craig ; Brose, Marcia S. ; Kim, Edward S. ; Johnson, David H. ; Peppercorn, Jeffrey M. ; Michels, Dina L. ; Storm, Courtney D. ; Schuchter, Lynn M. ; Rathmell, W. Kimryn. / Physician and stakeholder perceptions of conflict of interest policies in oncology. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 ; Vol. 31, No. 13. pp. 1677-1682.
@article{307a8df444564624875cba761d7edc4a,
title = "Physician and stakeholder perceptions of conflict of interest policies in oncology.",
abstract = "The landscape of managing potential conflicts of interest (COIs) has evolved substantially across many disciplines in recent years, but rarely are the issues more intertwined with financial and ethical implications than in the health care setting. Cancer care is a highly technologic arena, with numerous physician-industry interactions. The American Society of Clinical Oncology (ASCO) recognizes the role of a professional organization to facilitate management of these interactions and the need for periodic review of its COI policy (Policy). To gauge the sentiments of ASCO members and nonphysician stakeholders, two surveys were performed. The first asked ASCO members to estimate opinions of the Policy as it relates to presentation of industry-sponsored research. Respondents were classified as consumers or producers of research material based on demographic responses. A similar survey solicited opinions of nonphysician stakeholders, including patients with cancer, survivors, family members, and advocates. The ASCO survey was responded to by 1,967 members (1{\%} of those solicited); 80{\%} were producers, and 20{\%} were consumers. Most respondents (93{\%} of producers; 66{\%} of consumers) reported familiarity with the Policy. Only a small proportion regularly evaluated COIs for presented research. Members favored increased transparency about relationships over restrictions on presentations of research. Stakeholders (n = 264) indicated that disclosure was {"}very important{"} to {"}extremely important{"} and preferred written disclosure (77{\%}) over other methods. COI policies are an important and relevant topic among physicians and patient advocates. Methods to simplify the disclosure process, improve transparency, and facilitate responsiveness are critical for COI management.",
author = "Lockhart, {A. Craig} and Brose, {Marcia S.} and Kim, {Edward S.} and Johnson, {David H.} and Peppercorn, {Jeffrey M.} and Michels, {Dina L.} and Storm, {Courtney D.} and Schuchter, {Lynn M.} and Rathmell, {W. Kimryn}",
year = "2013",
month = "5",
day = "1",
doi = "10.1200/JCO.2012.47.5475",
language = "English (US)",
volume = "31",
pages = "1677--1682",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Physician and stakeholder perceptions of conflict of interest policies in oncology.

AU - Lockhart, A. Craig

AU - Brose, Marcia S.

AU - Kim, Edward S.

AU - Johnson, David H.

AU - Peppercorn, Jeffrey M.

AU - Michels, Dina L.

AU - Storm, Courtney D.

AU - Schuchter, Lynn M.

AU - Rathmell, W. Kimryn

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The landscape of managing potential conflicts of interest (COIs) has evolved substantially across many disciplines in recent years, but rarely are the issues more intertwined with financial and ethical implications than in the health care setting. Cancer care is a highly technologic arena, with numerous physician-industry interactions. The American Society of Clinical Oncology (ASCO) recognizes the role of a professional organization to facilitate management of these interactions and the need for periodic review of its COI policy (Policy). To gauge the sentiments of ASCO members and nonphysician stakeholders, two surveys were performed. The first asked ASCO members to estimate opinions of the Policy as it relates to presentation of industry-sponsored research. Respondents were classified as consumers or producers of research material based on demographic responses. A similar survey solicited opinions of nonphysician stakeholders, including patients with cancer, survivors, family members, and advocates. The ASCO survey was responded to by 1,967 members (1% of those solicited); 80% were producers, and 20% were consumers. Most respondents (93% of producers; 66% of consumers) reported familiarity with the Policy. Only a small proportion regularly evaluated COIs for presented research. Members favored increased transparency about relationships over restrictions on presentations of research. Stakeholders (n = 264) indicated that disclosure was "very important" to "extremely important" and preferred written disclosure (77%) over other methods. COI policies are an important and relevant topic among physicians and patient advocates. Methods to simplify the disclosure process, improve transparency, and facilitate responsiveness are critical for COI management.

AB - The landscape of managing potential conflicts of interest (COIs) has evolved substantially across many disciplines in recent years, but rarely are the issues more intertwined with financial and ethical implications than in the health care setting. Cancer care is a highly technologic arena, with numerous physician-industry interactions. The American Society of Clinical Oncology (ASCO) recognizes the role of a professional organization to facilitate management of these interactions and the need for periodic review of its COI policy (Policy). To gauge the sentiments of ASCO members and nonphysician stakeholders, two surveys were performed. The first asked ASCO members to estimate opinions of the Policy as it relates to presentation of industry-sponsored research. Respondents were classified as consumers or producers of research material based on demographic responses. A similar survey solicited opinions of nonphysician stakeholders, including patients with cancer, survivors, family members, and advocates. The ASCO survey was responded to by 1,967 members (1% of those solicited); 80% were producers, and 20% were consumers. Most respondents (93% of producers; 66% of consumers) reported familiarity with the Policy. Only a small proportion regularly evaluated COIs for presented research. Members favored increased transparency about relationships over restrictions on presentations of research. Stakeholders (n = 264) indicated that disclosure was "very important" to "extremely important" and preferred written disclosure (77%) over other methods. COI policies are an important and relevant topic among physicians and patient advocates. Methods to simplify the disclosure process, improve transparency, and facilitate responsiveness are critical for COI management.

UR - http://www.scopus.com/inward/record.url?scp=84884546497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884546497&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.47.5475

DO - 10.1200/JCO.2012.47.5475

M3 - Article

VL - 31

SP - 1677

EP - 1682

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -